Performance Accelerates Growth for 2007
PRINCETON, N.J., May 3 /PRNewswire/ -- Laureate Pharma, Inc., a full-
service biopharmaceutical development and protein production company, today
announced significant growth for the first quarter 2007, more than doubling
its revenues compared to the same period last year, and recognizing
increased demand for its contract biomanufacturing services. As part of its
growth strategy, Laureate is moving ahead with the expansion of its
workforce and its facility located in Princeton, NJ. The company renewed
and extended its lease term to year 2016, commissioned its brand new pilot
plant to accelerate non- cGMP production projects, entered into key
strategic alliances with Boehringer Ingelheim, formed a Scientific Advisory
Board and elected a new non-executive Chairman for its Board of Directors.
(Logo: http://www.newscom.com/cgi-bin/prnh/20020723/LPHARMLOGO )
"We have a very good start to the fiscal year as evidenced by solid
revenue results for the first quarter," said Robert Broeze, President and
Chief Executive Officer at Laureate Pharma. "We are thrilled by the rate at
which our company is growing. We have a strong pipeline of projects and are
continuing to win an impressive number of clients. We are focused on
executing upon our strategies and operational excellence, which will
further accelerate growth going forward."
"Laureate Pharma's impressive first quarter performance demonstrates
the success of the company strategy and the strength of the
infrastructure," said James A. Datin, Executive Vice President and Managing
Director of the Life Sciences Group at Safeguard Scientifics. "The solid
pipeline and strong momentum has uniquely positioned Laureate for continued
growth, capturing an increased market share of the cGMP industry."
Safeguard Scientifics acquired Laureate in December 2004, providing the
company with growth capital, operational and management support to achieve
its strategic plan.
About Laureate Pharma
Laureate Pharma, Inc. is a full-service biopharmaceutical development
and protein production company located in Princeton, New Jersey. Laureate
Pharma offers superior bioprocessing services that accelerate new products
from development through production. We provide a wide range of specialized
services from process design and development to full-scale cGMP production,
purification, aseptic filling, testing, validation, analytical services,
and regulatory support. Our business is focused on two active segments of
the biopharmaceutical industry: monoclonal antibodies and recombinant
protein products. Laureate Pharma is a wholly owned subsidiary of Safeguard
Scientifics, Inc. For more information, contact Michael Cavanaugh, Vice
President Sales, Marketing, and Business Development at (609) 919-3400, or
info@laureatepharma.com or visit our web site at http://www.laureatepharma.com.
About Safeguard
Safeguard Scientifics, Inc. (NYSE: SFE), a holding company, builds
value in growth-stage technology and life sciences businesses. We provide
growth capital as well as a range of strategic, operational and management
resources to our partner companies. Safeguard participates in growth buyout
financings, including corporate spinouts and management buyouts, expansion
financings, industry consolidations and early-stage financings.
http://www.safeguard.com.
SOURCE Laureate Pharma, Inc.
back to top
Related links: http://www.laureatepharma.com http://www.safeguard.com
Photo Notes: NewsCom: http://www.newscom.com/cgi-bin/prnh/20020723/LPHARMLOGO AP Archive: http://photoarchive.ap.org PRN Photo Desk, photodesk@prnewswire.com
CONTACT: Michael Cavanaugh, Vice President Sales, Marketing, and Business Development of Laureate Pharma, Inc., +1-609-919-3400, or info@laureatepharma.com
|